Erratum

Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (MAPLE): A randomized, double-blind, phase III study (Clin Cancer Res (2019) 25(2088–95)Doi:10.1158/1078-0432.CCR-18-2702)

Nicholas Thatcher, Jerome H. Goldschmidt, Michael Thomas, Michael Schenker, Zhiying Pan, Luis Paz-Ares Rodriguez, Valery Breder, G. Ostoros, Vladimir Hanes

Research output: Contribution to journalComment/debate

Abstract

In the original version of this article (1), Fig. 1 was incomplete and the "Methods" sections of both the abstract and the article stated that patients received drugs thrice weekly instead of every three weeks. These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors. Reference 1. Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares Rodriguez L, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced non-squamous non–small-cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res 2019;25:2088–95.

Original languageEnglish
Number of pages1
JournalClinical Cancer Research
Volume25
Issue number10
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Biosimilar Pharmaceuticals
Non-Small Cell Lung Carcinoma
Safety
Neoplasms
Emotions
Pharmaceutical Preparations
Bevacizumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Erratum : Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (MAPLE): A randomized, double-blind, phase III study (Clin Cancer Res (2019) 25(2088–95)Doi:10.1158/1078-0432.CCR-18-2702). / Thatcher, Nicholas; Goldschmidt, Jerome H.; Thomas, Michael; Schenker, Michael; Pan, Zhiying; Paz-Ares Rodriguez, Luis; Breder, Valery; Ostoros, G.; Hanes, Vladimir.

In: Clinical Cancer Research, Vol. 25, No. 10, 01.01.2019.

Research output: Contribution to journalComment/debate

@article{fd72f6ddacea4b729872f210f41e8591,
title = "Erratum: Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (MAPLE): A randomized, double-blind, phase III study (Clin Cancer Res (2019) 25(2088–95)Doi:10.1158/1078-0432.CCR-18-2702)",
abstract = "In the original version of this article (1), Fig. 1 was incomplete and the {"}Methods{"} sections of both the abstract and the article stated that patients received drugs thrice weekly instead of every three weeks. These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors. Reference 1. Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares Rodriguez L, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced non-squamous non–small-cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res 2019;25:2088–95.",
author = "Nicholas Thatcher and Goldschmidt, {Jerome H.} and Michael Thomas and Michael Schenker and Zhiying Pan and {Paz-Ares Rodriguez}, Luis and Valery Breder and G. Ostoros and Vladimir Hanes",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-19-1098",
language = "English",
volume = "25",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Erratum

T2 - Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (MAPLE): A randomized, double-blind, phase III study (Clin Cancer Res (2019) 25(2088–95)Doi:10.1158/1078-0432.CCR-18-2702)

AU - Thatcher, Nicholas

AU - Goldschmidt, Jerome H.

AU - Thomas, Michael

AU - Schenker, Michael

AU - Pan, Zhiying

AU - Paz-Ares Rodriguez, Luis

AU - Breder, Valery

AU - Ostoros, G.

AU - Hanes, Vladimir

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In the original version of this article (1), Fig. 1 was incomplete and the "Methods" sections of both the abstract and the article stated that patients received drugs thrice weekly instead of every three weeks. These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors. Reference 1. Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares Rodriguez L, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced non-squamous non–small-cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res 2019;25:2088–95.

AB - In the original version of this article (1), Fig. 1 was incomplete and the "Methods" sections of both the abstract and the article stated that patients received drugs thrice weekly instead of every three weeks. These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors. Reference 1. Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares Rodriguez L, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced non-squamous non–small-cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res 2019;25:2088–95.

UR - http://www.scopus.com/inward/record.url?scp=85065798156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065798156&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-19-1098

DO - 10.1158/1078-0432.CCR-19-1098

M3 - Comment/debate

VL - 25

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -